Bayer concludes acquisition of Blackford Analysis
Berlin: Bayer has announced that the company has completed the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd.
As a result, Blackford, which has a presence in the United Kingdom and the United States, is now a wholly owned subsidiary of Bayer AG. The company provides infrastructure and access to a rich clinical application ecosystem focused on imaging and analytics. It continues to operate on an arm’s length basis to preserve its entrepreneurial culture as an essential pillar for nurturing successful innovation. Blackford remains accountable to advance its technology, channel partnerships and ClinApp portfolio while benefiting from the experience, infrastructure and reach of Bayer as a global pharmaceutical company.
“The official closing of the acquisition of Blackford marks an important step in implementing our strategy to drive innovation in radiology, including the development and adoption of AI within the clinical workflow,” said Gerd Krüger, President Radiology, Bayer. “Bayer is a leader in key radiology areas with a comprehensive portfolio and a deep medical understanding across a multitude of diseases. We are excited that we are now able to join forces with the exceptional Blackford team to use our combined expertise for the benefit of patients and their treating physicians.”
Read also: Bayer submits Aflibercept 8 mg for regulatory approval in two major retinal eye diseases in EU
“Blackford has built a strong reputation in the AI platform segment for radiology, with a wide portfolio of 3rd party products and a strong deployed base of hospitals, radiology groups and imaging centers,” said Ben Panter, Chief Executive Officer of Blackford. “Combining our knowledge and experience with Bayer will enable us to provide solutions to deliver ongoing clinical value to radiologists and their referrers.”
